Answers are grounded in this paper and cite their sources.
Historically, sequencing has been the key technology to assess variation in the genetic code, and has been widely accepted in clinical diagnostics of genetic disease.The advent of next-generation sequencing (NGS) methods increased the size of the analyzed target by several orders of magnitude, while at the same time drastically reducing the cost of sequencing.Current research allows sequencing of germline and tumor whole genomes.However, with the arrival of cutting-edge technology to the clinical diagnostic field, strict regulatory oversight is required to use the advances of the latest research when applied to routine clinical practice.We discuss the differences between sequencing in a research setting and sequencing in a clinical diagnostics setting, as applied to next-generation technology.T he invention, implementation, and wide adoption of next-generation sequencing (NGS) technology has expanded the horizons of genomics and significantly upgraded the genetic testing toolkit.Research efforts of impressive scale, such as the International Cancer Genome Consortium (ICGC, see icgc.org) and The Cancer Genome Atlas (TCGA, see cancergenome.nih.gov), and the efforts of the University of Cambridge, Genomics England, and Illumina to sequence 10,000 whole genomes of children and adults with rare genetic diseases (Moran 2014), are well underway.Without a doubt, projects of this scale became possible because of the phenomenal power of massively parallel sequencing, commonly referred to as next-generation sequencing.Along with the incredible capabilities afforded in research studies, the horizon of clin-ical diagnostics has expanded as well.For a number of years, dideoxy-terminator (Sanger) sequencing was the main tool of genetic diagnostics laboratories.A typical Sanger sequencing experiment results in 500-600 base pairs of sequence and covers, on average, a single exon of a gene.In contrast, NGS has enabled inherited disease testing in panels of genes ( 10 -200 genes), exomes ( 20,000 genes) and whole human genomes (6 Gbp), diagnostics in solid tumors and infectious diseases, as well as noninvasive prenatal testing.The reasonably accessible cost of NGS instrumentation and consumables, along with the general acceptance of genetic tests in the clinical community and the availability of insurance reimbursement, led to the great increase in the number of genetic service providers.Currently, there are 684 molecular diagnostics laboratories in the GeneTests
No takes yet. Share an insight, caveat, or question.
Shevchenko et al. (2016) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: